GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea
GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea
葛蘭素史克的 EAGLE-1 三期數據顯示，Gepotidacin有可能成爲無併發症的泌尿生殖系統淋病的新口服治療選擇
- Gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatment
- EAGLE-1 is the third positive pivotal trial for gepotidacin, a potential first-in-class oral antibiotic as part of GSK's industry-leading infectious diseases portfolio
- Gepotidacin的微生物學成功率爲92.6％，並且不遜於領先的聯合療法
- EAGLE-1 是 gepotidacin 的第三項陽性關鍵試驗，作爲葛蘭素史克行業領先的傳染病產品組合的一部分，它是一種潛在的首創口服抗生素
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。